Deidre Wilkins

1.4k total citations · 1 hit paper
29 papers, 745 citations indexed

About

Deidre Wilkins is a scholar working on Epidemiology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Deidre Wilkins has authored 29 papers receiving a total of 745 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 8 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Deidre Wilkins's work include Respiratory viral infections research (10 papers), Immunodeficiency and Autoimmune Disorders (4 papers) and Neonatal Respiratory Health Research (4 papers). Deidre Wilkins is often cited by papers focused on Respiratory viral infections research (10 papers), Immunodeficiency and Autoimmune Disorders (4 papers) and Neonatal Respiratory Health Research (4 papers). Deidre Wilkins collaborates with scholars based in United States, Sweden and United Kingdom. Deidre Wilkins's co-authors include Stephen G. Farmer, Sonya Meeker, Ronald M. Burch, Clay W. Scott, Mark T. Esser, Brendan J. Canning, Michael E. Abram, Anastasia A. Aksyuk, Linda A. Sygowski and Matthew F. Peters and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and PEDIATRICS.

In The Last Decade

Deidre Wilkins

28 papers receiving 711 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

2023 70 citations Deidre Wilkins, Yuan Yuan et al. Nature Medicine profile →

Peers

Countries citing papers authored by Deidre Wilkins

Since Specialization

Citations

This map shows the geographic impact of Deidre Wilkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deidre Wilkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deidre Wilkins more than expected).

Fields of papers citing papers by Deidre Wilkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deidre Wilkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deidre Wilkins. The network helps show where Deidre Wilkins may publish in the future.

Co-authorship network of co-authors of Deidre Wilkins

This figure shows the co-authorship network connecting the top 25 collaborators of Deidre Wilkins. A scholar is included among the top collaborators of Deidre Wilkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deidre Wilkins. Deidre Wilkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY) 2024 ·Vaccine ·Kevin M. Tuffy, (unknown), Joseph B. Domachowske, Kenji Furuno, Hong Ji, Shabir A. Madhi, Vaishali S. Mankad, Ulrika Wählby Hamrén, Tonya Villafana, Yingyi Wang, Elizabeth J. Kelly, Deidre Wilkins	1
2	Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY) 2024 ·Clinical Infectious Diseases ·Douglas Arbetter, Vancheswaran Gopalakrishnan, Anastasia A. Aksyuk, (unknown), Yue Chang, Ron Dagan, Mark T. Esser, Laura L. Hammitt, Vaishali S. Mankad, Xavier Sáez‐Llorens, D. T. Shen, Amanda Leach, Elizabeth J. Kelly, Tonya Villafana, Deidre Wilkins	6
3	RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing 2024 ·PEDIATRICS ·Deidre Wilkins, Ulrika Wählby Hamrén, (unknown), Lindsay E. Clegg, Joseph B. Domachowske, Janet A. Englund, William J. Muller, Amanda Leach, Elizabeth J. Kelly, Tonya Villafana	12
4	Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity 2024 ·Frontiers in Immunology ·(unknown), Anastasia A. Aksyuk, Deidre Wilkins, (unknown), Dongmei Lan, Kathryn Shoemaker, Hong‐Van Tieu, Magdalena E. Sobieszczyk, Ann R. Falsey, Elizabeth J. Kelly	2
5	Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection 2023 ·Frontiers in Immunology ·Tyler Brady, Corinne Cayatte, Tiffany Barnes, Scott D. Speer, Hong Ji, (unknown), (unknown), Deidre Wilkins, Kevin M. Tuffy, Elizabeth J. Kelly	20
6	1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY) 2023 ·Open Forum Infectious Diseases ·Deidre Wilkins, Ulrika Wählby Hamrén, Yue Chang, Joseph B. Domachowske, Janet A. Englund, William J. Muller, Amanda Leach, Tonya Villafana, Elizabeth J. Kelly	1
7	Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants breakdown → 2023 ·Nature Medicine ·Deidre Wilkins, Yuan Yuan, Yue Chang, Anastasia A. Aksyuk, (unknown), Ulrika Wählby Hamrén, (unknown), Michael E. Abram, Amanda Leach, Tonya Villafana, Mark T. Esser	70
8	2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study 2023 ·Open Forum Infectious Diseases ·Christopher Morehouse, (unknown), Anastasia A. Aksyuk, Tyler Brady, Kevin M. Tuffy, Hong Ji, Elizabeth J. Kelly, Deidre Wilkins	2
9	AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection 2022 ·Cell Reports Medicine ·Anastasia A. Aksyuk, Himanshu Bansal, Deidre Wilkins, (unknown), Stephanie Sproule, (unknown), (unknown), William R. Hartman, Magdalena E. Sobieszczyk, Ann R. Falsey, Elizabeth J. Kelly	13
10	Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017−2018 INFORM-RSV Study 2020 ·Journal of Clinical Microbiology ·David E. Tabor, Fiona Fernandes, Annefleur C Langedijk, Deidre Wilkins, Robert Jan Lebbink, Andrey Tovchigrechko, Alexey Ruzin, Leyla Kragten‐Tabatabaie, Hong Jin, Mark T. Esser, Louis Bont, Michael E. Abram	73
11	Characterization of human respiratory syncytial virus (RSV) isolated from HIV‐exposed‐uninfected and HIV‐unexposed infants in South Africa during 2015‐2017 2020 ·Influenza and Other Respiratory Viruses ·Hui Liu, Bin Lü, David E. Tabor, Andrey Tovchigrechko, Deidre Wilkins, Hong Jin, Shabir A. Madhi, (unknown), Mark T. Esser, Marta C. Nunes	12
12	A first-in-human phase I study of JNJ-26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced cancer with evidence of target modulation and antitumor activity. 2011 ·Journal of Clinical Oncology ·Richard D. Baird, B. Venugopal, (unknown), (unknown), Montserrat Blanco-Codesido, Edward J. Saunders, (unknown), D. Crawford, Peter Stephens, Deidre Wilkins, (unknown), Ann Forslund, Johan W. Smit, (unknown), Nele Fourneau, Peter Hellemans, Johann S. de Bono, Ruth Plummer, Udai Banerji, T. R. J. Evans	1
13	Evaluation of Cellular Dielectric Spectroscopy, a Whole-Cell, Label-Free Technology for Drug Discovery on Gi-Coupled GPCRs 2007 ·SLAS DISCOVERY ·Matthew F. Peters, (unknown), Deidre Wilkins, Linda A. Sygowski, (unknown), Jianwei Liu, Clay W. Scott	66
14	Novel Small Molecule Inhibitors of Caspase-3 Block Cellular and Biochemical Features of Apoptosis 2003 ·Journal of Pharmacology and Experimental Therapeutics ·Clay W. Scott, (unknown), Deidre Wilkins, Robert T. Jacobs, (unknown), William J. Frazee, Ratan V. Bhat, (unknown), David Aharony	48
15	A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry 2003 ·Analytical Biochemistry ·Clay W. Scott, Deidre Wilkins, (unknown), Denis Crankshaw	30
16	MOLECULAR CLONING OF THE GUINEA-PIG IL-5 RECEPTOR α AND β SUBUNITS AND RECONSTITUTION OF A HIGH AFFINITY RECEPTOR 2000 ·Cytokine ·Clay W. Scott, Naomi J. Logsdon, Deidre Wilkins, (unknown), (unknown), (unknown), Alexander Graham	3
17	Expression and in vitro properties of guinea pig IL‐5: Comparison to human and murine orthologs 2000 ·Mediators of Inflammation ·Clay W. Scott, (unknown), (unknown), (unknown), (unknown), Deidre Wilkins	2
18	Cloning, sequencing and functional expression of a guinea pig lung bradykinin B2 receptor 1998 ·European Journal of Pharmacology ·Stephen G. Farmer, (unknown), Deidre Wilkins, Alexander Graham	29
19	Design of potent, cyclic peptide bradykinin receptor antagonists from conformationally constrained linear peptides 1993 ·Journal of Medicinal Chemistry ·Sarvajit Chakravarty, Deidre Wilkins, Donald J. Kyle	26
20	Adenosine receptor‐mediated contraction and relaxation of guinea‐pig isolated tracheal smooth muscle: effects of adenosine antagonists 1988 ·British Journal of Pharmacology ·Stephen G. Farmer, Brendan J. Canning, Deidre Wilkins	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact